30 results about "Lung deposition" patented technology

The invention discloses an inhalation administration device and a design method, and mainly relates to the technical field of medical instruments. The device comprises a capsule base, a capsule body, a capsule cabin and a suction nozzle, an inner cavity of the suction nozzle is of an inverted trapezoid structure, and in other words, the diameter of the section is increased by 0.033 mm every time the inner area of the suction nozzle is raised by 1 mm from the bottom end to the top end. According to the design, by optimizing the internal flow field of the suction nozzle, the dispersity of medicine particles can be remarkably improved, wall surface deposition is reduced, and therefore the dispersity of the medicine particles and the lung deposition efficiency are improved. The invention also provides a design method based on lattice Boltzmann method-immersion boundary method-large eddy simulation multi-physics field coupling numerical simulation, and by setting specific performance evaluation parameters, the structure optimization of the inverted trapezoidal suction nozzle can be efficiently and accurately guided. An in-vitro deposition test shows that the performance of the device is superior to or equivalent to that of a commercially available product.

The invention discloses a multi-substituted cyclodextrin supramolecular material as well as a preparation method and application thereof and a pharmaceutical composition, and relates to the technical field of supramolecular materials, and the multi-substituted cyclodextrin supramolecular material is obtained by coordination of multi-substituted cyclodextrin and metal ions. The CD-pMOF prepared by the preparation method disclosed by the invention has relatively strong drug loading capacity, and shows an excellent protective effect on unstable drugs; and the prepared CD-pMOFs with different sizes respectively have relatively good upper respiratory tract and lung deposition effects, and have wide application prospects in inhalation drug delivery systems.

An innovative imaging-based subject-specific whole-lung deposition model is provided. Computed tomography (CT) lung volumetric images at total lung capacity (TLC) may be used to segment airways and lobes, and registration of CT images at TLC and functional residual capacity (FRC) provided metrics of regional air volume changes. A volume-filling technique may then be used to generate the entire conducting airways and acinar units. In each acinar unit, a respiratory airway model may be generated based on existing morphometric data. The flow distributions in conducting airways and to acinar units may be calculated by a one-dimensional (ID) computational fluid dynamics (CFD) model. With the simulated airflow field, deposition fractions may be calculated using deposition probability formulae adjusted with an enhancement factor to account for the effects of transient secondary flow and realistic airway geometry.

The present invention relates to an atomizing device, which comprises: an atomizing chamber; and an aerosol output channel, connecting the atomizing chamber with the external environment; wherein, the conveying direction of at least part of the aerosol output channel intersects with the air inlet direction of the aerosol output channel, and / or the conveying direction of at least part of the aerosol output channel intersects with the air outlet direction of the aerosol output channel. In the above-mentioned atomizing device, the aerosol particles flowing through the aerosol output channel undergo irregular motion, thereby increasing the probability of aerosol particles colliding with each other, and aerosol particles with smaller particle sizes combine to form aerosol particles with larger particle sizes, thereby effectively reducing the proportion of aerosol particles with a particle size of approximately 0.62 μm and 0.78 μm, and increasing the proportion of aerosol particles with a particle size of approximately 1.32 μm. Therefore, most of the aerosol particles output by the atomizing device of the present application have a particle size of 1 μm-5 μm, have a high lung deposition rate, and effectively improve the effective utilization of the active ingredients in the aerosol.

The invention belongs to the technical field of biological medicines, and particularly provides an ALO-coated F127-MOF nano-composite as well as a preparation method and application thereof. According to the ALO (at) F127-MOF nano compound, UiO-66-NH2 MOF with a pluronic F-127 coating is used as a nano carrier, and aloperine is loaded on the nano carrier. The nano compound is used for treating ALI, the solubility, stability and bioavailability of the traditional Chinese medicine aloperine are effectively improved, and the synergistic effect of sustained release of aloperine, ROS neutralization and effective targeting is achieved. The aerosolization-based delivery approach ensures better oxygenation, lower systemic toxicity, and better pulmonary deposition. The invention provides a new treatment method for noninvasive acute lung injury treatment.

Provided in the present invention are a suspended triple inhalation aerosol composition and a preparation method therefor. The aerosol composition comprises fluticasone furoate, vilanterol trifenatate, glycopyrrolate, a diluent, a surfactant and a propellant; has higher drug-delivery efficiency and drug-delivery dose, and higher lung deposition; and has the effects of better ameliorating Mch-induced elevated pulmonary resistance and decreased pulmonary compliance, thereby facilitating improvement to medication safety and patient compliance.

The invention relates to an inhalation dry powder preparation containing a salmeterol and tiotropium salt composition and a preparation method of the inhalation dry powder preparation, and belongs to the technical field of pharmaceutical preparations. The preparation comprises a long-acting beta-2 adrenergic receptor agonist (LABA) salmeterol and a long-acting anticholinergic drug (LAMA) tiotropium salt, and the efficient synergistic effect of the two drugs is achieved by optimizing a drug micronization process, a carrier particle design, a carrier material and a preparation process. The medicine can penetrate into a lung target region, so that precise treatment is realized. A powder mist inhalation device CN219423486U disclosed by Nanchang large pharmaceutical industry limited company is adopted as a delivery device, and the lung deposition rate and delivery efficiency of the medicine are remarkably improved by controlling the particle size of the medicine, the particle property of a carrier and the uniformity of the preparation. In addition, the invention further provides a preparation method of the preparation, the preparation method comprises the processes of medicine micronization, mixing homogenization and packaging, and the stability and dosage accuracy of the preparation are ensured. Experiments show that in an accelerated stability investigation period as long as 6 months, the drug content, impurity level and fine particle fraction in the preparation are kept stable and do not change significantly, and it is proved that the preparation has good physical and chemical stability and storage performance. The preparation has quick-acting and long-acting bronchiectasia effects, is suitable for long-term management of moderate and severe asthma and chronic obstructive pulmonary disease (COPD), and can significantly improve the medication convenience and treatment compliance of patients.

The present invention discloses drug combination microspheres, a preparation method, and a raw material composition. The raw material composition of the drug microspheres of the present invention comprises the following components: formoterol fumarate, mometasone furoate, and a solvent. The drug combination microspheres of the present invention have a reduced bulk density and significantly reduce the residue of the prepared powder inhaler in the inhalation device and capsule shell, which is beneficial for increasing lung deposition and has good drug development prospects.

The invention belongs to the technical field of atomizers, and relates to a metal atomization sheet for medical atomization and a manufacturing method. Comprising a metal sheet, the metal sheet is circular, a plurality of micropores are uniformly formed in the center of the metal sheet, and the micropores are trumpet-shaped. The metal atomizing sheet adopts a circular design, so that the metal atomizing sheet can be better matched with the internal structure of the vibrating screen hole atomizer, is convenient to mount and fix, and improves the convenience of assembly and the stability of the structure. And the micropores are formed in the center of the metal sheet and are uniformly distributed, so that the medicine can uniformly pass through the micropores in the vibration process, local blockage or non-uniform atomization is avoided, and the consistency and stability of atomized particles are ensured. The micropores are designed in a horn shape, and the gradually-expanded structure of the micropores is beneficial to forming a more stable gas-liquid interface when the medicine passes through, reducing the flow resistance, improving the atomization efficiency and the uniformity of atomized particles, and being beneficial to deposition of the medicine in the lung.

The invention relates to the technical field of child atomizers, and discloses a child self-adaptive atomizer with a multi-stage atomization particle size control function, the child self-adaptive atomizer comprises a filter assembly, the side face of the filter assembly is fixedly connected with a first breather pipe, and the end, away from the filter assembly, of the first breather pipe is fixedly connected with a regulation and control host; a second ventilation pipe penetrates through the side wall of the regulation and control main machine, and an atomization mechanism is arranged at the end, away from the regulation and control main machine, of the second ventilation pipe. 99.97% of particulate matters and harmful gases in the air can be effectively intercepted through a multi-level purification structure (primary-effect non-woven fabric, medium-effect activated carbon and high-efficiency HEPA) of the filter assembly, and a clean air source is provided for children; an annular pipeline of the atomization mechanism and a super energy transducer are cooperatively designed, the Venturi atomization technology of an air pump assembly is combined, the ultrasonic frequency and the air pump power are intelligently adjusted through a regulation and control host, multi-stage switching of the atomization particle size is achieved, physiological characteristics of the respiratory tract of children are precisely adapted, and the lung deposition rate of medicine is increased by 40% or above.

The invention discloses a rifapentine capsule type dry powder inhaler and a preparation method thereof, the capsule type dry powder inhaler comprises a capsule shell and a capsule content, and the capsule content comprises the following components in parts by weight: 1 part of rifapentine, 1-30 parts of a carrier and 0.01-1 part of a flow aid. According to the invention, micronized drug bulk drugs and appropriate excipients are in the form of capsules, and atomized drugs are actively inhaled into the lungs by a patient through a specially-made dry powder inhalation device. The delivery efficiency of the preparation is high, and the lung deposition rate is high; the particle size of the preparation and the stability of the preparation are high, and the compatibility between raw materials and auxiliary materials is good. The rifapentine capsule type dry powder inhaler disclosed by the invention has no gastrointestinal tract degradation effect and no liver first-pass effect, the medicine can directly act on the lung, the absorption is quick, and the effect is quick after administration; meanwhile, local administration is realized, the dosage is obviously reduced, and toxic and side effects are small. The preparation method disclosed by the invention is simple and easy to implement, has no too high requirements on technical equipment, and is suitable for domestic industrial production.

The invention provides a fluticasone furoate micellar solution. The fluticasone furoate micellar solution comprises fluticasone furoate, a lipophilic component and a nonionic surfactant. According to the fluticasone furoate pharmaceutical composition, the dissolution rate and the absorption rate of fluticasone furoate on nasal mucosa and alveolar mucosa can be remarkably improved, and the administration dosage can be further reduced while the same curative effect is obtained, so that the toxic and side effects are reduced. The aerosol inhalation powder is especially suitable for aerosol inhalation, can provide better pulmonary deposition, and is especially suitable for nasal administration to reduce the administration dosage and improve the bioavailability.

Disclosed is an analysis system for determining the deposition of an aerosol for a breathing apparatus with an analysis device comprising an air duct, a first air sensor, a control unit and an application component, wherein the air duct is set up to guide air along the first air sensor to the application component and vice versa, the first air sensor is set up to detect at least a first air flow parameter of the air guided along the first air sensor, and the control unit is set up to control the first air sensor in such a way that a time characteristic of the first air flow parameter can be measured as a first measurement result, and the first measurement result can be transmitted to an assessment device.

The invention provides an inhalable nano-gelling enzyme for treating pulmonary ECM (extracellular matrix) deposition as well as a preparation method and application of the inhalable nano-gelling enzyme. According to the preparation method disclosed by the invention, aldehyde groups in the oxidized sodium alginate and amino groups in ECM digestion enzyme molecules are subjected to Schiff base reaction to prepare the nanogelling enzyme, so that intervention of a toxic cross-linking agent is avoided, and the enzyme loading efficiency is greatly improved. The nano gel enzyme has the advantages of enzyme protection, good biocompatibility, high drug loading capacity, targeted delivery and industrial production. The nano-gelling enzyme is applied to preparation of medicines for treating lung diseases, can be administrated through aerosol inhalation, can effectively reduce excessive ECM deposition in the lung diseases, can digest ECM barriers, and can recover pulmonary alveolar structures and relieve dyspnea symptoms at the same time.

The invention belongs to the field of pharmaceutical preparations, and provides an auxiliary material system for pulmonary administration of insoluble drugs and a preparation method of the auxiliary material system. According to the invention, a collaborative design of lipid-coated indissolvable drug nanocrystal core-shell particles and a ternary lipid dispersion intermediate is adopted, and an anti-solvent precipitation in-situ coating and high-pressure microjet refining technology is adopted; the preparation method comprises the following steps: coating the outer surface of a nintedanib nanocrystal with a lipid shell layer composed of dipalmitoyl-sn-glycerol-3-phosphorylcholine, cholesterol and propylene glycol caprylate to form core-shell particles with the mass median particle size D50 value of 150-250 nm and the volume distribution D90 value of less than or equal to 400 nm. According to the invention, high drug loading capacity, low viscosity and atomizable property are realized, lung deposition distribution and long-term particle size stability are optimized, the contradiction between high solid content and rheological property, low irritation and colloid stability, and atomization efficiency and core-shell structure integrity in lung administration of insoluble drugs is effectively relieved, and the preparation method has wide clinical application value.

The invention relates to the technical field of medicines, in particular to an inhalable pharmaceutical composition containing a soluble guanylate cyclase (SGC) receptor stimulant and application of the inhalable pharmaceutical composition, and clinical adverse reactions of medicines can be remarkably reduced. According to the pharmaceutical composition, the administration dosage is reduced, on the premise that the drug effect is kept unchanged, the hypotension side effect caused in the administration process is reduced, and the normal blood pressure level is rapidly recovered after administration. The pharmaceutical composition provided by the invention needs to be combined with matched instruments for use, wherein the pharmaceutical composition comprises an SGC receptor stimulant drug and other inhalable pharmaceutic adjuvants. The lung deposition rate can reach more than 40% under the combination of a specific prescription and instruments. Through inhalation of the pharmaceutical composition, an SGC receptor stimulant can enter blood more quickly, and pharmacokinetic parameters such as Tmax are improved.

The invention relates to the technical field of medicines, and discloses a lung anti-inflammatory spray based on aloe polysaccharide, which realizes efficient anti-inflammatory (IL-6) and targeted delivery (deposition rate of 85%) by optimizing the proportion of natural components (8% of aloe polysaccharide, 1.5% of dipotassium glycyrrhizinate and 2% of andrographolide) and an atomization process (particle size of 2 mu m). According to the lung anti-inflammatory spray based on the aloe polysaccharide and the preparation method of the lung anti-inflammatory spray, through the synergistic effect of the aloe polysaccharide (8%) and natural anti-inflammatory components (1.5% of dipotassium glycyrrhizinate and 2% of andrographolide), the proinflammatory factor level (IL-6 is reduced by 60%, and TNF-alpha is reduced by 62%) is remarkably reduced, the inhibition rate on an LPS-induced mouse pneumonia model reaches 88% or above, and the lung anti-inflammatory spray has the advantages that the lung anti-inflammatory spray has a good application prospect. The effect of the dexamethasone spray is better than that of a single-component or chemically synthesized drug (such as dexamethasone), drug particles are efficiently deposited in an alveolar area through an optimized atomization process (the spraying particle size is 2 microns), the lung deposition rate is larger than or equal to 85% and far exceeds that of a conventional spray (generally smaller than or equal to 70%), and the bioavailability is remarkably improved.

The invention relates to the technical field of biological medicine, and discloses a lung targeting mRNA delivery construction method based on particle size control, which comprises the following steps: selecting a nano carrier material with biocompatibility and adjustable property; designing and modifying the nano-carrier material, and endowing the nano-carrier material with specific functional groups; and establishing a mathematical physical model, calculating the deposition behavior of the particles in the airflow based on fluid mechanics and particle dynamics theories, and calculating the deposition efficiency of the particles in the lung according to the particle size. The micro-fluidic technology and the temperature and pH response type polymer are combined, the particle size is accurately adjusted, the particle size can be controllably changed in different physiological environments, and the precision and flexibility of particle size distribution are improved. Adaptive optimization is carried out through simulated annealing and a genetic algorithm, lung deposition, cellular uptake and carrier stability are comprehensively considered, and the delivery efficiency is maximized. The model established by combining fluid mechanics and particle dynamics theories optimizes the relationship between the particle size and the cellular uptake efficiency.

Provided is a computer implemented method for determining airway deposition of an inhaled substance in a zone of a lung of a subject, comprising: —receiving a patient dataset of the subject comprising a parameter set of two or more parameters and corresponding values, wherein the parameters in the parameter set form at least four dimensionless numbers in a dimensionless correlation specific to the zone, —determining, from the dimensionless correlation and the corresponding values of the parameters in the parameter set, the airway deposition of the inhaled substance in the zone of the lung of the subject.

The invention discloses an intelligent electric dosing device applied to a pressure quantitative aerosol, and aims to solve the problems of difficulty in hand-mouth coordination and low medicine utilization rate in use of the traditional pressure quantitative aerosol (pMDI). The device comprises a shell, a mouthpiece, a medicine bottle fixing mechanism, an electric driving mechanism, an air suction detection module and a control module. The medicine bottle fixing mechanism is movably arranged on the shell and used for fixing a medicine bottle in a repeatable assembling and disassembling mode and enabling a medicine bottle nozzle to be aligned with and stretch into an air inlet of the mouthpiece. The electric driving mechanism is used for driving the medicine bottle fixing mechanism to move to extrude the nozzle to release medicine; the inspiration detection module is used for detecting the inspiration action of a patient; the control module automatically controls the electric driving mechanism to execute pesticide spraying according to the air suction signal. By means of an air suction synchronous automatic triggering mechanism, the medicine taking correctness and the medicine lung deposition rate are remarkably improved.

The invention discloses an aerosol inhalation preparation based on traditional Chinese medicine components and an application of the aerosol inhalation preparation in replacement of tobacco products. The aerosol inhalation preparation comprises a lung clearing group, an aerosol inhalation group and an aerosol inhalation group, wherein the lung clearing group comprises herba houttuyniae extract, folium mori flavone and total anthraquinone of semen cassiae; a qi tonifying group: ginseng extract and cordycepin; the kidney tonifying group comprises cistanche polysaccharide and eucommia total glycoside; a spleen tonifying and blood circulation promoting group: pachymaran and tanshinone; the tranquilizing and sedating group comprises agilawood volatile oil and lily saponin; an atomization carrier: plant glycerin and propylene glycol; the flavoring agent comprises menthol and glycyrrhizic acid. The invention relates to the technical crossing field of traditional Chinese medicines and modern inhalation preparations. According to the aerosol inhalation preparation containing the traditional Chinese medicine components and the application of the aerosol inhalation preparation in replacing tobacco products, through traditional Chinese medicine compound compatibility and a nanometer wrapping technology, the natural aerosol preparation which has the functions of efficient smoking cessation (the smoking desire is reduced by 78% in 24 hours), lung function repair (IL-6 is reduced by 42%) and good taste acceptability (accepted by 92%) is provided, the lung deposition rate of the aerosol inhalation preparation reaches 65%, and the aerosol inhalation preparation is excellent in stability; and a safe and effective solution is provided for tobacco replacement.

The invention relates to a dry powder inhalation composition as well as a preparation method and a drug delivery system thereof. The dry powder inhalation composition comprises a base material and an active component, and the preparation method comprises the following steps: carrying out first high shear mixing on the base material to prepare an intermediate material; carrying out second high shear mixing on the intermediate material and the active component; wherein the rotating speed of the first high-shear mixing is greater than or equal to 150rpm; the rotating speed of the second-time high-shear mixing is greater than or equal to 150rpm. The preparation method of the dry powder inhalation composition is simple in step and short in time consumption, and meanwhile, the high lung deposition rate of the medicine can be kept.

The invention provides a refenasin inhalation solution and a preparation method thereof. The refenasin inhalation solution comprises an active component refenasin, a pH buffer agent, an osmotic pressure regulator and a stabilizer. The stability of the rafenasin inhalation solution under ultrasonic atomization can be remarkably improved, the storage stability is good, and the effect of the better lung deposition rate is achieved.

The present invention discloses a nanoparticle for treating lung diseases, and its preparation method and application. The nanoparticle for treating lung diseases provided by the present invention comprises a nanoparticle carrier and a nucleic acid molecule; the raw materials of the nanoparticle carrier include the TM2 and DOPE, and the molar ratio of the two is 1:2. The nucleic acid-encapsulated nanoparticles provided by the present invention can efficiently deliver nucleic acid molecules to the lungs and downregulate the expression of pathogenic proteins; they can significantly increase the deposition of drugs in the lungs, effectively ensuring the effect after administration, and at the same time have the advantages of simple administration, non-invasiveness, and high safety. It is a highly innovative and efficient lung deposition method with good application prospects in the treatment of lung-related diseases.

The invention provides a nemategravir inhalant and a preparation method and application thereof, and belongs to the technical field of medicines.The nemategravir inhalant comprises nemategravir, water, a surfactant and an auxiliary, has the high lung deposition rate, good stability and low irritation and can overcome the defects of existing nemategravir oral tablets. After the nemategravir inhalant prepared by the embodiment of the invention is inhaled, the residence time of nemategravir in lung tissues can be maintained for more than 12 hours.

The application discloses an inhaled ascorbic acid powder aerosol and a preparation method thereof, and relates to the technical field of inhaled administration, which is composed of ascorbic acid and a diluent, and is in the form of a dry powder, wherein the weight percentage of the ascorbic acid is 10%-100%, and the weight percentage of the diluent is 0-90%; the dry powder aerosol realizes lung target delivery through inhaled administration, has good fluidity and lung deposition effect, and is mainly used for treating acute lung injury, and provides an efficient and safe treatment scheme for lung diseases.

The present invention discloses a rhodomyrtone inhalation suspension and a preparation method thereof. The rhodomyrtone inhalation suspension is obtained by mixing the following raw materials and auxiliary materials in percentage by weight: rhodomyrtone 0.02%-1%, surfactant 0.005%-0.1%, suspending agent 0-2.2%, pH regulator 0.01%-0.03%, flocculant 0.02%-0.04%, stabilizer 0.005%-0.015%, osmotic pressure regulator 0.7%-1.1%, and water as the balance; the surfactant is polysorbate; and the suspending agent is povidone K30 and / or microcrystalline cellulose-sodium carboxymethylcellulose. The inhalation suspension has a high effective lung deposition rate and accurate delivery dose, and can accurately deliver a set dose of rhodomyrtone directly to lung lesions, exerting its antiviral efficacy.

The invention discloses inhalation type quercetin dry powder inhalation and a preparation method thereof, and belongs to the technical field of inhalation administration. Aiming at the problems of low oral bioavailability, poor targeting property and the like of quercetin, the dry powder inhalation is prepared from the following components in percentage by weight: 10 to 100 percent of quercetin, 0 to 85 percent of diluent and 0 to 5 percent of taste indicator, and the particle size of quercetin particles is D90lt; 20 [mu] m. The preparation method comprises the following steps: crushing the quercetin and the diluent, mixing with the taste indicator, sieving, spheroidizing in a spheroidizing disc to prepare spherical particles, and finally filling into an inhaler. The dry powder aerosol realizes lung targeted delivery through inhalation administration, has good fluidity and lung deposition effect, is mainly used for treating lung nodules, and provides an efficient and safe treatment scheme for lung diseases.

The invention provides an atomization device and method for a pediatric internal medicine respiratory system. The method comprises the following steps: determining respiratory characteristics when a target child uses an atomizer for atomization; classifying the breathing states of the target child according to the breathing characteristics to obtain a plurality of breathing modes, and further determining a coupling coefficient between each breathing mode and atomization particle size distribution in combination with atomization particle records in the atomization process; the inspiration flow of the target child in the current breathing mode is obtained, and the particle size prediction value of the atomized particles in the current breathing mode is determined according to the inspiration flow and all the coupling coefficients; determining the dynamic compensation amount of the particle size of the atomized particles in the current breathing mode by combining the particle size predicted value with the lung deposition rate of the atomized particles; and adjusting the nozzle aperture of the adjustable nozzle in the atomizer according to the dynamic compensation amount. By the adoption of the scheme, the deposition efficiency of the atomized particles can be improved by adjusting the atomization particle size of the atomizer in a self-adaptive mode.

Provided are a budesonide pharmaceutical composition, particularly a budesonide inhalation spray, and a preparation process therefor. The budesonide pharmaceutical composition comprises budesonide, ethanol, a stabilizer, and / or an antioxidant. The budesonide pharmaceutical composition, particularly the budesonide inhalation spray, has the advantages of good stability, uniform spray microparticle distribution, a high lung deposition rate, and / or convenient administration, which is suitable for industrial production.